GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opiant Pharmaceuticals Inc (NAS:OPNT) » Definitions » PS Ratio

Opiant Pharmaceuticals (Opiant Pharmaceuticals) PS Ratio : 7.48 (As of May. 14, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Opiant Pharmaceuticals PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Opiant Pharmaceuticals's share price is $20.65. Opiant Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2022 was $2.76. Hence, Opiant Pharmaceuticals's PS Ratio for today is 7.48.

Warning Sign:

Opiant Pharmaceuticals Inc stock PS Ratio (=7.48) is close to 3-year high of 7.64

The historical rank and industry rank for Opiant Pharmaceuticals's PS Ratio or its related term are showing as below:

OPNT' s PS Ratio Range Over the Past 10 Years
Min: 0.74   Med: 2.69   Max: 33.06
Current: 7.48

During the past 13 years, Opiant Pharmaceuticals's highest PS Ratio was 33.06. The lowest was 0.74. And the median was 2.69.

OPNT's PS Ratio is not ranked
in the Biotechnology industry.
Industry Median: 9.14 vs OPNT: 7.48

Opiant Pharmaceuticals's Revenue per Sharefor the three months ended in Sep. 2022 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2022 was $2.76.

Warning Sign:

Opiant Pharmaceuticals Inc revenue growth has slowed down over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Opiant Pharmaceuticals was -60.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was 15.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was 3.30% per year.

During the past 13 years, Opiant Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 74.30% per year. The lowest was -7.90% per year. And the median was 13.20% per year.

Back to Basics: PS Ratio


Opiant Pharmaceuticals PS Ratio Historical Data

The historical data trend for Opiant Pharmaceuticals's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opiant Pharmaceuticals PS Ratio Chart

Opiant Pharmaceuticals Annual Data
Trend Jul12 Jul13 Jul14 Jul15 Jul16 Jul17 Dec18 Dec19 Dec20 Dec21
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.58 3.19 2.01 1.25 4.89

Opiant Pharmaceuticals Quarterly Data
Oct17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.68 4.89 3.38 2.36 3.89

Competitive Comparison of Opiant Pharmaceuticals's PS Ratio

For the Biotechnology subindustry, Opiant Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Opiant Pharmaceuticals's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opiant Pharmaceuticals's PS Ratio distribution charts can be found below:

* The bar in red indicates where Opiant Pharmaceuticals's PS Ratio falls into.



Opiant Pharmaceuticals PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Opiant Pharmaceuticals's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=20.65/2.76
=7.48

Opiant Pharmaceuticals's Share Price of today is $20.65.
Opiant Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.76.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Opiant Pharmaceuticals  (NAS:OPNT) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Opiant Pharmaceuticals PS Ratio Related Terms

Thank you for viewing the detailed overview of Opiant Pharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Opiant Pharmaceuticals (Opiant Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
233 Wilshire Boulevard, Suite 280, Santa Monica, CA, USA, 90401
Opiant Pharmaceuticals Inc is a specialty pharmaceutical company operating in the US. It develops pharmacological treatments for substance use, addictive and eating disorders. The company has developed NARCAN, a Nasal Spray for treatment to reverse opioid overdoses. The company's pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD) and Acute Cannabinoid Overdose (ACO). The majority of the revenue is generated in the form of Royalty and licensing.
Executives
David D O'toole officer: Chief Financial Officer 1640 MARENGO STREET, LOS ANGELES CA 90033
Ellison Mark Jason Heath other: UK Managing Director C/O OPIANT PHARMACEUTICALS, INC., 201 SANTA MONICA BLVD., SUITE 500, SANTA MONICA CA 90401
Roger Crystal director, 10 percent owner, officer: Chief Executive Officer 445 PARK AVE, 10TH FL., NEW YORK NY 10022
Phil Skolnick officer: Chief Scientific Officer C/O DOV PHARMACEUTICAL, INC., 433 HACKENSACK AVENUE, HACKENSACK NJ 07601
Brian Gorman other: General Counsel 233 WILSHIRE BLVD, SUITE 280, SANTA MONICA CA 90401
Matthew R. Ruth officer: Chief Commercial Officer 233 WILSHIRE BLVD., SUITE 280, SANTA MONICA CA 90401
Michael Sinclair director, 10 percent owner, officer: Executive Chairman 86 GLOUCESTER PLACE, LONDON XX W1U6HP
Craig A Collard director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Ann L. Macdougall director C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Thomas T. Thomas director C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Masuoka K. Lorianne director C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Gabrielle Alison Silver director C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Rahsaan Thompson other: General Counsel 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Aziz Mottiwala officer: Chief Commercial Officer 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Richard J Daly director 355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134

Opiant Pharmaceuticals (Opiant Pharmaceuticals) Headlines

From GuruFocus

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPNT, WAFD, LBC

By Value_Insider Value_Insider 11-15-2022